©2024 Stanford Medicine
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Not Recruiting
Trial ID: NCT00947856
Purpose
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with
brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab
vedotin study.
Official Title
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Eligibility
Inclusion Criteria:
- Participated in a previous brentuximab vedotin study.
- CD30-positive hematologic malignancy.
- At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For
retreatment, patients must have previously achieved either complete or partial
remission with brentuximab vedotin and experienced disease progression after
discontinuing the prior brentuximab vedotin study.
Exclusion Criteria:
Withdrew consent to participate in any prior brentuximab vedotin study.
Intervention(s):
drug: brentuximab vedotin
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061